HESTERBIO Stock Overview
Manufactures and trades in veterinary vaccines and animal health products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Hester Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,382.05 |
| 52 Week High | ₹3,379.00 |
| 52 Week Low | ₹1,292.85 |
| Beta | 0.73 |
| 1 Month Change | -0.14% |
| 3 Month Change | -2.90% |
| 1 Year Change | 62.50% |
| 3 Year Change | -7.01% |
| 5 Year Change | 61.86% |
| Change since IPO | 467.90% |
Recent News & Updates
Recent updates
Hester Biosciences Limited's (NSE:HESTERBIO) CEO Compensation Looks Acceptable To Us And Here's Why
Aug 23
What Hester Biosciences Limited's (NSE:HESTERBIO) 26% Share Price Gain Is Not Telling You
Jul 27Revenues Working Against Hester Biosciences Limited's (NSE:HESTERBIO) Share Price
Jun 12Hester Biosciences (NSE:HESTERBIO) Has Announced A Dividend Of ₹10.00
Aug 01Would Hester Biosciences Limited (NSE:HESTERBIO) Be Valuable To Income Investors?
Mar 03Did You Miss Hester Biosciences' (NSE:HESTERBIO) Whopping 308% Share Price Gain?
Feb 13What Is The Ownership Structure Like For Hester Biosciences Limited (NSE:HESTERBIO)?
Jan 26Who Has Been Buying Hester Biosciences Limited (NSE:HESTERBIO) Shares?
Jan 11
Hester Biosciences Limited's (NSE:HESTERBIO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Dec 25Are Hester Biosciences's (NSE:HESTERBIO) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 10These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively
Nov 25How Does Hester Biosciences Limited (NSE:HESTERBIO) Fare As A Dividend Stock?
Nov 10If You Had Bought Hester Biosciences (NSE:HESTERBIO) Shares Five Years Ago You'd Have Earned 212% Returns
Oct 26What Type Of Shareholders Own The Most Number of Hester Biosciences Limited (NSE:HESTERBIO) Shares?
Oct 05Are Strong Financial Prospects The Force That Is Driving The Momentum In Hester Biosciences Limited's NSE:HESTERBIO) Stock?
Sep 14These 4 Measures Indicate That Hester Biosciences (NSE:HESTERBIO) Is Using Debt Extensively
Aug 25How Much Are Hester Biosciences Limited (NSE:HESTERBIO) Insiders Taking Off The Table?
Aug 07Hester Biosciences Limited (NSE:HESTERBIO) Is Yielding 0.5% - But Is It A Buy?
Jul 07Shareholder Returns
| HESTERBIO | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -2.8% | -4.6% | -4.3% |
| 1Y | 62.5% | 40.8% | 19.1% |
Return vs Industry: HESTERBIO exceeded the Indian Biotechs industry which returned 40.8% over the past year.
Return vs Market: HESTERBIO exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| HESTERBIO volatility | |
|---|---|
| HESTERBIO Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: HESTERBIO has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: HESTERBIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 642 | Rajiv Gandhi | www.hester.in |
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek’s disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis.
Hester Biosciences Limited Fundamentals Summary
| HESTERBIO fundamental statistics | |
|---|---|
| Market cap | ₹20.34b |
| Earnings (TTM) | ₹234.69m |
| Revenue (TTM) | ₹3.16b |
86.7x
P/E Ratio6.4x
P/S RatioIs HESTERBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HESTERBIO income statement (TTM) | |
|---|---|
| Revenue | ₹3.16b |
| Cost of Revenue | ₹939.87m |
| Gross Profit | ₹2.22b |
| Other Expenses | ₹1.99b |
| Earnings | ₹234.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 27.59 |
| Gross Margin | 70.30% |
| Net Profit Margin | 7.42% |
| Debt/Equity Ratio | 76.1% |
How did HESTERBIO perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield27%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 17:32 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hester Biosciences Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vaishali Kumar Parkar | BOB Capital Markets Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Siddhant Khandekar | ICICIdirect.com |